How does PlexusDx's Precision Peptide Genetic Test help optimize my semaglutide schedule
Lozano Villanueva JL, et al
176 SugiharaG.HashimotoK.IwataY.NakamuraK.TsujiiM.TsuchiyaK
Explore personalized support GLP-1s can be effective, but theyre not the only tool in the toolbox, says Rush weight loss expert Elizabeth Blankenship, NP
- This study investigated the association of semaglutide 2.4 mg with major adverse cardiovascular events among individuals with overweight/obesity without diabetes who had risk factors for atherosclerotic cardiovascular disease.- This study investigated the association of semaglutide 2.4 mg with major adverse cardiovascular events among individuals with overweight/obesity without diabetes who had risk factors for atherosclerotic cardiovascular disease.- 48,184 patients initiating semaglutide 2.4 mg were propensity-score matched 1:2 to those not on semaglutide 2.4 mg (96,368 individuals).- In this study, semaglutide 2.4 mg was associated with a lower risk of incident major adverse cardiovascular events and heart failure composite outcomes.- Exploratory analyses further demonstrated consistent lower risks of obesity-related outcomes, including incident type 2 diabates, major adverse kidney events, acute kidney injury, major obesity-related adverse events, and all-cause hospitalization.Association between semaglutide 2.4 mg and risk of cardiovascular events in people with overweight or obesity without atherosclerotic cardiovascular disease in the real-world: The SCORE primary prevention study (open access) doi.org/10.1016/j.ajpc
However, smokers are generally advised to avoid beta-carotene and any supplements that contain it
